BioLife Sciences Retains Benzinga for Marketing Campaign
BioLife Sciences Retains Benzinga for Marketing Campaign
HENDERSON, Nev., Aug. 09, 2022 (GLOBE NEWSWIRE) -- BioLife Sciences Inc. (OTCPK: BLFE) (the "Company" or BioLife), announced today that it has retained Benzinga to launch marketing and advertising services on their network of media channels.
2022年8月9日，內華達州亨德森(Global Newswire)--BioLife Science Inc.(OTCPK：BLFE)(以下簡稱“公司”或“BioLife”)今天宣佈，它已聘請Benzinga在其媒體渠道網絡上推出營銷和廣告服務。
BioLife Sciences was recently qualified for a Regulation A+ (Tier 1) Offering by the SEC, aimed at achieving various business goals and directives.
生物生命科學最近獲得了美國證券交易委員會A+法規(第1級)的資格，旨在實現各種商業目標和指令。
Nika Jaksic, COO of BioLife Sciences, said: "We chose to launch our marketing campaigns in phases, first by bringing in SmallCapVoice.com and then following that up with GS Whitney & Co, and now building upon that solid foundation with Benzinga.com, and their syndicated partners, whose reach and expertise are without question. Benzinga is one of the top financial media outlets which empowers investors with highly informative and high-quality content. We are thrilled to have entered into an agreement with them."
生物生命科學公司首席運營官尼卡·雅克西奇説：“我們選擇分階段開展營銷活動，首先引入SmallCapVoice.Com，然後與GS Whitney&Co合作，現在與Benzinga.com及其辛迪加合作伙伴建立堅實的基礎，他們的覆蓋範圍和專業知識是毋庸置疑的。Benzinga是頂級金融媒體之一，為投資者提供高度信息量和高質量的內容。我們很高興能與他們達成協議。”
Benzinga, since its launch in 2010, has developed into a major hub for actionable information on capital markets. With over two million readers each month, Benzinga continues to empower new generations of investors by connecting the world with news, data, and education, making the path to financial prosperity easier for everyone.
Benzinga自2010年推出以來，已發展成為資本市場可操作信息的主要樞紐。Benzinga每月擁有200多萬讀者，通過將世界與新聞、數據和教育聯繫起來，繼續增強新一代投資者的能力，使每個人都更容易實現金融繁榮。
About BioLife Sciences Inc.
關於生物生命科學公司
BioLife Sciences Inc. specializes in moving innovative products from the lab or small-scale production into wider market adoption. Its core business develops, licenses and distributes antimicrobial products and disruptive technology. One of BioLife Sciences' core building block strategies is to develop, partner and assist innovative companies with the commercialization of leading-edge technologies.
生物生命科學公司專門致力於將創新產品從實驗室或小規模生產轉移到更廣泛的市場採用。其核心業務是開發、許可和分銷抗菌產品和顛覆性技術。生物生命科學的核心組成部分戰略之一是開發、合作並協助創新公司將尖端技術商業化。
About Benzinga
關於本辛加
Benzinga empowers individual investors by keeping them one step ahead. Benzinga gives access to all the financial news and content that is available. Instead of giving financial advice, Benzinga gives you the news to make informed decisions to take control of your financial future.
Benzinga通過讓個人投資者領先一步來賦予他們權力。Benzinga提供了所有可用的財經新聞和內容。Benzinga不給你財務建議，而是給你新聞，讓你做出明智的決定，控制你的財務未來。
Disclaimer
免責
The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the ability of the Corporation to complete a qualifying transaction. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
本新聞稿中的信息包括與管理層對未來事件、預期、計劃和前景的看法有關的某些信息和聲明，這些信息和聲明構成前瞻性聲明。這些陳述是基於受重大風險和不確定因素影響的假設。由於這些風險和不確定因素，以及各種因素的影響，實際結果、預期、成就或業績可能與這些前瞻性陳述中預期和表明的大不相同。本新聞稿中的前瞻性陳述包括但不限於該公司完成合格交易的能力。許多因素都可能導致實際結果與這些前瞻性陳述以及未來結果大不相同。儘管本公司認為前瞻性陳述中反映的預期是合理的，但它不能保證任何前瞻性陳述的預期將被證明是正確的。除非法律另有要求，否則本公司無意更新或修訂任何前瞻性陳述，以反映實際結果，無論是由於新信息、未來事件、假設的變化、影響此類前瞻性陳述的因素的變化或其他原因。
Contact Information:
ir@biolifesciences.com
US & Canada: 1 (833) 919-1037
聯繫方式：
郵箱：ir@biolifesciences.com
美國和加拿大：1(833)919-1037
譯文內容由第三人軟體翻譯。